Literature DB >> 19920059

Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.

D Tassinari1, F Drudi2, L Lazzari-Agli2, P Tombesi3, S Sartori3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19920059     DOI： 10.1093/annonc/mdp538

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  [Implications of modern anticancer therapies for palliative care concepts].

Authors:  B Alt-Epping; F Nauck
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

2.  Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment.

Authors:  Chengqi Yu; Leilei Jiang; Dan Yang; Xin Dong; Rong Yu; Huiming Yu
Journal:  Onco Targets Ther       Date:  2022-10-17       Impact factor: 4.345

3.  Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life.

Authors:  Wolfgang Schuette; Hans Tesch; Hartwig Büttner; Thomas Krause; Victoria Soldatenkova; Clemens Stoffregen
Journal:  BMC Cancer       Date:  2012-01-13       Impact factor: 4.430

4.  Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).

Authors:  Baohui Han; Kai Li; Yizhuo Zhao; Baolan Li; Ying Cheng; Jianying Zhou; You Lu; Yuankai Shi; Zhehai Wang; Liyan Jiang; Yi Luo; Yiping Zhang; Cheng Huang; Qiang Li; Guoming Wu
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.